If OPT-302 in wAMD works in a Phase III study with the same results as Phase IIb it will be the standard of care as it has shown more efficacy than the current SoC. That alone will make physicians want to use it and patients to demand it.
Here is some more info from a blog on it (here) that discusses why pharma would want to own the rights to OPT-302.
In terms of the market cap, I would say that it is actually undervalued. Kodiac (KOD:NASDAQ), a direct competitor (with an inferior product it seems), is worth USD2.86bn. That is triple OPT.
If OPT-302 in wAMD works in a Phase III study with the same...
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
44.0¢ |
Change
0.030(7.32%) |
Mkt cap ! $535.5M | |||
| Open | High | Low | Value | Volume |
| 42.0¢ | 44.0¢ | 42.0¢ | $2.647M | 6.082M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 66295 | 44.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 44.5¢ | 53912 | 10 |
View Market Depth
| Last trade - 15.53pm 29/07/2024 (20 minute delay) ? |
| OPT (ASX) Chart |